ARQT Historical PE Ratio Notes

— Arcutis Biotherapeutics (ARQT) is a biopharmaceutical company focused on developing & commercializing innovative therapies for immune-mediated dermatological diseases, such as psoriasis and atopic dermatitis. The company’s pipeline centers around unique topical treatments, aiming to improve efficacy & safety versus traditional approaches. For an investor analyzing ARQT's historical price-to-earnings (PE) ratio, it’s important to note that as a development-stage biotech firm, Arcutis has historically recorded significant net losses rather than earnings, due to heavy R&D expenses and minimal product revenue until recently. As a result, the historical PE ratio may often be negative or listed as “N/A,” especially prior to key product launches. When analyzing historical PE ratio data, be aware that spikes or drops in the ratio can reflect milestone events, such as clinical trial data releases or regulatory approvals, which affect investor sentiment & price, sometimes ahead of revenue growth or profitability. Thus, ARQT's PE history may not be directly comparable to mature pharmaceutical companies, but rather reflects market expectations around future earnings potential rather than current profits.

On this page we presented the Arcutis Biotherapeutics Historical PE Ratio information for Arcutis Biotherapeutics' stock. The average ARQT historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is 78.0. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average ARQT historical PE based on this TTM earnings result method is NA. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this ARQT historical PE result, against the recent PE: when this page was posted on 5/13/2026, the most recent closing price for ARQT had been 21.69, and the most recent quarterly earnings result, annualized, was 0.52. Meanwhile, the most recent TTM earnings summed to NA. From these numbers, we calculate the recent ARQT PE on 5/13/2026 based on annualized quarterly EPS was 41.7. Based on ARQT's history, that recent PE is low relative to the historical average, with the recent PE 46.5% lower than the historical average PE across our data set for Arcutis Biotherapeutics.

For self directed investors doing their due diligence on ARQT or any other given stock, valuation analysis for ARQT can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Arcutis Biotherapeutics PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for ARQT. Thanks for visiting, and the next time you need to research ARQT Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.